

FORM PTO-1449

U.S. Dept. of Commerce

Atty Docket No.


Serial No.

P1055R1

09/291,925

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)



Applicant

Ashkenazi et al.

Filing Date

14 Apr 1999

Group

3737

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
RZ	1	4,766,075	23.08.88	Goeddel et al.	11	11	
RZ	2	4,795,706	03.01.89	Hsiung et al.	11	11	
RZ	3	5,702,938	30.12.97	Goeddel et al.	11	11	

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
RZ	4	WO 92/04444	19.03.92	PCT	11	11		
RZ	5	WO 96/17067	06.06.96	PCT	11	11		

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

RZ	6	Alexander and Elder, "Carbohydrate dramatically influences immune reactivity of antisera to viral glycoprotein antigens" <u>Science</u> 226(4680):1328-1330 (Dec 14, 1984)					
	7	Aruffo et al., "CD44 is the Principal Cell Surface Receptor for Hyaluronate" <u>Cell</u> 61:1303-1313 (June 29, 1990)					
	8	Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoaderin" <u>Proc. Natl. Acad. Sci.</u> 88:10535-10539 (1991)					
	9	Ashwell and Harford, "Carbohydrate-specific receptors of the liver" <u>Annual Review of Biochemistry</u> 51:531-554 (1982)					
	10	Ashwell and Morrell, "The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins" <u>Advances in Enzymology</u> 41:99-128 (1974)					
	11	Bennett et al., "Extracellular Domain-IgG Fusion Proteins for Three Human Natriuretic Peptide Receptors. Hormone Pharmacology and Application to Solid Phase Screening of Synthetic Peptide Antisera" <u>The Journal of Biological Chemistry</u> 266(34):23060-23067 (Dec 5, 1991)					
	12	Berg and Grinnell, "Signal and propeptide processing of human tissue plasminogen activator: activity of a pro-TPA derivative" <u>Biochemical and Biophysical Research Communications</u> 179(3):1289-1296 (Sep 30, 1991)					
	13	Berman et al., "Engineering Glycoproteins for Use as Pharmaceuticals" <u>Trends in Biotechnology</u> 3(2):51-53 (February 1985)					
	14	Berman et al., "Expression and Immunogenicity of the Extracellular Domain of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, gp160" <u>Journal of Virology</u> 63(8):3489-3498 (1989)					
	15	Byrn et al., "Biological Properties of a CD4 Immunoaderin" <u>Nature</u> 344:667-670 (April 12, 1990)					
	16	Capon et al., "Designing CD4 Immunoaderins for AIDS Therapy" <u>Nature</u> 337:525-531 (February 9, 1989)					
	17	Caton et al., "The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype)" <u>Cell</u> 31(2 Pt 1):417-427 (Dec 1982)					
	18	Chalupny et al., "T-cell activation molecule 4-1BB binds to extracellular matrix proteins" <u>Proc. Natl. Acad. Sci. USA</u> 89(21):10360-10364 (Nov 1, 1992)					
RZ	19	Claffey et al., "Structural requirements for dimerization, glycosylation, secretion, and biological function of VPF/VEGF" <u>Biochimica et Biophysica Acta</u> 1246(1):1-9 (Jan 5, 1995)					

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office AUG 09 1999 PATENT & TRADEMARK OFFICE 690		Atty Docket No. P1055R1	Serial No. 09/291,925
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Ashkenazi et al.	
				Filing Date 14 Apr 1999	Group 3737
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
20	Collier et al., "Specific glycosylation site mutations of the insulin receptor $\alpha$ subunit impair intracellular transport" <u>Biochemistry</u> 32(30):7818-7823 (Aug 3, 1993)				
21	Culp et al., "Regulated expression allows high level production and secretion of HIV-1 gp120 envelope glycoprotein in Drosophila Schneider cells" <u>Bio/Technology</u> 9(2):173-177 (Feb 1991)				
22	Dorner et al., "The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins" <u>Journal of Cell Biology</u> 105(6 Pt 1):2665-2674 (Dec 1987)				
23	Dube et al., "Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion, and biological function" <u>Journal of Biological Chemistry</u> 263(33):17516-17521 (Nov 25, 1988)				
24	Feng et al., "The structure of the TATA-less rat tissue-type plasminogen activator gene. Species-specific sequence divergences in the promoter predict differences in regulation of gene expression" <u>Journal of Biological Chemistry</u> 265(4):2022-2027 (Feb 5, 1990)				
25	Fiedler and Simons, "The role of N-glycans in the secretory pathway" <u>Cell</u> 81(3):309-312 (May 5, 1995)				
26	Flack et al., "Site-directed mutagenesis defines the individual roles of the glycosylation sites on follicle-stimulating hormone" <u>Journal of Biological Chemistry</u> 269(19):14015-14020 (May 13, 1994)				
27	Gallagher et al., "Glycosylation requirements for intracellular transport and function of the hemagglutinin of influenza virus" <u>Journal of Virology</u> 66(12):7136-7145 (Dec 1992)				
28	Gray et al., "Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein" <u>Proc. Natl. Acad. Sci. USA</u> 87(19):7380-7384 (Oct 1990)				
29	Helenius, A., "How N-linked oligosaccharides affect glycoprotein folding in the endoplasmic reticulum" <u>Molecular Biology of the Cell</u> 5(3):253-265 (Mar 1994)				
30	Kery et al., "Ligand recognition by purified human mannose receptor" <u>Archives of Biochemistry &amp; Biophysics</u> 298(1):49-55 (Oct 1992)				
31	Kohn et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor" <u>Proc. Natl. Acad. Sci. USA</u> 87:8331-8335 (1990)				
32	Kornfeld et al., "Assembly of Asparagine-linked Oligosaccharides" <u>Ann. Rev. Biochem.</u> 54:631-664 (1985)				
33	Krasney and Young, "Further aspects of IL-1 $\beta$ secretion revealed by transfected monkey kidney cells" <u>Cytokine</u> 4(2):134-143 (Mar 1992)				
34	Kurschner et al., "Construction, purification, and characterization of new interferon $\gamma$ (IFN $\gamma$ ) inhibitor proteins. Three IFN $\gamma$ receptor-immunoglobulin hybrid molecules" <u>Journal of Biological Chemistry</u> 267(13):9354-9360 (May 5, 1992)				
35	Lasky et al., "Neutralization of the AIDS Retrovirus by Antibodies to a Recombinant Envelope Glycoprotein" <u>Science</u> 233:209-212 (1986)				
36	Lesslauer, "Recombinant Soluble Tumor Necrosis Factor Receptor Proteins Protect Mice From Lipopolysaccharide-induced lethality" <u>European Journal of Immunology</u> 21:2883-2886 (1991)				
37	Li et al., "Effects of inefficient cleavage of the signal sequence of HIV-1 gp120 on its association with calnexin, folding, and intracellular transport" <u>Proc. Natl. Acad. Sci. USA</u> 93(18):9606-9611 (Sep 3, 1996)				
38	Linsley et al., "Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation" <u>Journal of Experimental Medicine</u> 173:721-730 (1991)				
39	Linsley et al., "CTLA-4 is a second receptor for the B cell activation antigen B7" <u>Journal of Experimental Medicine</u> 174:561-569 (1991)				
Examiner <i>Robert L. Linsley</i>				Date Considered 9/25/90	

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 608, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

